TickerFacts.

BioNexus Gene Lab Corp (BGLC): R&D Expense

Annual figures by period end, from SEC filings.

$50.7K
Year ended 2025-12-31
$54.1K
Trailing 12 months to 2026-06-30
$55.0K2023-12-31: $55.0K2024-12-31: $47.5K2025-12-31: $50.7K$50.7K
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$50.7K+6.6%2026-04-14, From 2025-01-01
2024-12-31$47.5K-13.6%2026-04-14, From 2024-01-01
2023-12-31$55.0Kn/a2025-04-15, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
BioNexus Gene Lab Corp (BGLC)2025-12-31$50.7K+6.6%
Exagen Inc. (XGN)2025-12-31$6.25M+16.4%
Personalis, Inc. (PSNL)2025-12-31$50.26M+2.8%
Biodesix Inc (BDSX)2025-12-31$12.00M+25.5%
YD Bio Ltd (YDES)2025-12-31$1.60M+226.1%
GRAIL, Inc. (GRAL)2025-12-31$195.79M-39.3%
BillionToOne, Inc. (BLLN)2025-12-31$49.38M+34.9%
Fulgent Genetics, Inc. (FLGT)2025-12-31$53.91M+10.4%
Castle Biosciences Inc (CSTL)2025-12-31$51.85M-0.4%

Compare BGLC, XGN, PSNL, BDSX side by side · Screen every company in Services-Medical Laboratories ↗